AU2016360634B2 - A complex of a glucopyranosyl derivative and preparation method and use thereof - Google Patents
A complex of a glucopyranosyl derivative and preparation method and use thereof Download PDFInfo
- Publication number
- AU2016360634B2 AU2016360634B2 AU2016360634A AU2016360634A AU2016360634B2 AU 2016360634 B2 AU2016360634 B2 AU 2016360634B2 AU 2016360634 A AU2016360634 A AU 2016360634A AU 2016360634 A AU2016360634 A AU 2016360634A AU 2016360634 B2 AU2016360634 B2 AU 2016360634B2
- Authority
- AU
- Australia
- Prior art keywords
- complex
- inhibitor
- compound
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QCFIQACOJYJUMT-YFKPBYRVSA-N CC([C@H](CC1)NC1=O)=O Chemical compound CC([C@H](CC1)NC1=O)=O QCFIQACOJYJUMT-YFKPBYRVSA-N 0.000 description 1
- GFBDVZZUUCSGRZ-AQOUKQHESA-N CCOc1ccc(Cc(cc([C@]([C@@H]([C@H]([C@@H]2OCc3ccccc3)OCc3ccccc3)OCc3ccccc3)(OC3)O[C@]23C=O)cc2)c2Cl)cc1 Chemical compound CCOc1ccc(Cc(cc([C@]([C@@H]([C@H]([C@@H]2OCc3ccccc3)OCc3ccccc3)OCc3ccccc3)(OC3)O[C@]23C=O)cc2)c2Cl)cc1 GFBDVZZUUCSGRZ-AQOUKQHESA-N 0.000 description 1
- LWWWIBNUAGDGDO-WQVQVPTFSA-N CCOc1ccc(Cc(cc([C@]([C@@H]([C@H]2C)O)(OC3)O[C@]3([C@@H](C)O)[C@H]2O)cc2)c2Cl)cc1 Chemical compound CCOc1ccc(Cc(cc([C@]([C@@H]([C@H]2C)O)(OC3)O[C@]3([C@@H](C)O)[C@H]2O)cc2)c2Cl)cc1 LWWWIBNUAGDGDO-WQVQVPTFSA-N 0.000 description 1
- YQRVGYKYLKAJCM-GFUJKPJOSA-N CCOc1ccc(Cc2cc([C@@H]([C@@H]([C@H]3OCc4ccccc4)OCc4ccccc4)OC(CO)(CO)[C@H]3OCc3ccccc3)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@@H]([C@@H]([C@H]3OCc4ccccc4)OCc4ccccc4)OC(CO)(CO)[C@H]3OCc3ccccc3)ccc2Cl)cc1 YQRVGYKYLKAJCM-GFUJKPJOSA-N 0.000 description 1
- PFDMQVYEYSQAHM-QPEGLIRHSA-N CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3OCc4ccccc4)OCc4ccccc4)(OC)OC(CO)(CO)[C@H]3OCc3ccccc3)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@]([C@@H]([C@H]3OCc4ccccc4)OCc4ccccc4)(OC)OC(CO)(CO)[C@H]3OCc3ccccc3)ccc2Cl)cc1 PFDMQVYEYSQAHM-QPEGLIRHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510851466 | 2015-11-27 | ||
| CN201510851466.7 | 2015-11-27 | ||
| PCT/CN2016/107543 WO2017088839A1 (en) | 2015-11-27 | 2016-11-28 | A complex of a glucopyranosyl derivative and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016360634A1 AU2016360634A1 (en) | 2018-06-07 |
| AU2016360634B2 true AU2016360634B2 (en) | 2020-05-21 |
Family
ID=58763019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016360634A Active AU2016360634B2 (en) | 2015-11-27 | 2016-11-28 | A complex of a glucopyranosyl derivative and preparation method and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10555930B2 (https=) |
| EP (1) | EP3371199B1 (https=) |
| JP (1) | JP6916180B2 (https=) |
| CN (1) | CN106810582B (https=) |
| AU (1) | AU2016360634B2 (https=) |
| CA (1) | CA3005920C (https=) |
| ES (1) | ES3005482T3 (https=) |
| WO (1) | WO2017088839A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778336B (zh) * | 2016-08-24 | 2022-09-27 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的结晶形式 |
| CN108239123B (zh) * | 2016-12-27 | 2021-08-27 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的共晶、制备方法和应用 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN110407891A (zh) * | 2019-07-31 | 2019-11-05 | 扬子江药业集团北京海燕药业有限公司 | 一种sglt-2抑制剂中间体的精制方法 |
| CN114796250A (zh) * | 2021-01-27 | 2022-07-29 | 宜昌东阳光长江药业股份有限公司 | 一种含有吡喃葡萄糖基衍生物的药物组合物 |
| WO2022204907A1 (en) * | 2021-03-30 | 2022-10-06 | Sunshine Lake Pharma Co., Ltd. | Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative |
| CN115141235B (zh) * | 2021-03-30 | 2024-08-09 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的l-焦谷氨酸共晶的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015027963A1 (zh) * | 2013-09-02 | 2015-03-05 | 四川海思科制药有限公司 | 芳环类衍生物、其药物组合物及其应用 |
| WO2015043511A1 (en) * | 2013-09-27 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2016173425A1 (en) | 2015-04-30 | 2016-11-03 | Sunshine Lake Pharma Co., Ltd. | A glucopyranosyl derivative and preparation method and uses thereof |
-
2016
- 2016-11-28 CA CA3005920A patent/CA3005920C/en active Active
- 2016-11-28 US US15/778,220 patent/US10555930B2/en active Active
- 2016-11-28 JP JP2018527236A patent/JP6916180B2/ja active Active
- 2016-11-28 AU AU2016360634A patent/AU2016360634B2/en active Active
- 2016-11-28 WO PCT/CN2016/107543 patent/WO2017088839A1/en not_active Ceased
- 2016-11-28 ES ES16868062T patent/ES3005482T3/es active Active
- 2016-11-28 EP EP16868062.7A patent/EP3371199B1/en active Active
- 2016-11-28 CN CN201611070532.8A patent/CN106810582B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015027963A1 (zh) * | 2013-09-02 | 2015-03-05 | 四川海思科制药有限公司 | 芳环类衍生物、其药物组合物及其应用 |
| WO2015043511A1 (en) * | 2013-09-27 | 2015-04-02 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1254667A1 (en) | 2019-07-26 |
| CA3005920A1 (en) | 2017-06-01 |
| CN106810582B (zh) | 2019-12-31 |
| CN106810582A (zh) | 2017-06-09 |
| JP2018535237A (ja) | 2018-11-29 |
| WO2017088839A1 (en) | 2017-06-01 |
| CA3005920C (en) | 2023-08-22 |
| EP3371199B1 (en) | 2024-12-25 |
| US10555930B2 (en) | 2020-02-11 |
| JP6916180B2 (ja) | 2021-08-11 |
| EP3371199A4 (en) | 2019-06-12 |
| AU2016360634A1 (en) | 2018-06-07 |
| EP3371199A1 (en) | 2018-09-12 |
| ES3005482T3 (en) | 2025-03-14 |
| US20180344689A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016360634B2 (en) | A complex of a glucopyranosyl derivative and preparation method and use thereof | |
| JP7060298B1 (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体 | |
| CN107698569B (zh) | 作为jak抑制剂的联吡唑衍生物 | |
| CN108239123B (zh) | 吡喃葡萄糖基衍生物的共晶、制备方法和应用 | |
| CN106674294B (zh) | 吡喃葡萄糖基衍生物的结晶形式 | |
| JP7068743B2 (ja) | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 | |
| TWI823420B (zh) | 用作cdk激酶抑制劑的化合物及其應用 | |
| JP2018537486A (ja) | キノロン類似体及びその塩の結晶形 | |
| CN107778336B (zh) | 吡喃葡萄糖基衍生物的结晶形式 | |
| US10335401B2 (en) | Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity | |
| WO2016074566A1 (zh) | 一类葡萄糖苷衍生物及其药用组合物 | |
| CN111978325B (zh) | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 | |
| HK1254667B (en) | A complex of a glucopyranosyl derivative and preparation method and use thereof | |
| EP4635947A2 (en) | Crystal form of glucopyranosyl derivative and use thereof | |
| JP2024045832A (ja) | Ｇｌｐ－１受容体アゴニスト作用剤および抗肥満作用の関与する疾患の治療剤を組み合わせることを特徴とする医薬 | |
| CN118206517A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| CN118206518A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| NZ585307A (en) | Octahydroquinolizines for antidiabetic treatment | |
| TW202102487A (zh) | N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途 | |
| CN118206516A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| WO2018235785A1 (ja) | Ｍｇａｔ２阻害活性を有するジヒドロピリドン誘導体 | |
| CN121159540A (zh) | 一种三唑并嘧啶类化合物及其组合物、用途 | |
| WO2017128042A1 (zh) | 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY Free format text: FORMER APPLICANT(S): SUNSHINE LAKE PHARMA CO., LTD. |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SUNSHINE LAKE PHARMA CO., LTD. Free format text: FORMER APPLICANT(S): NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) |